KroniKare Pte Ltd.

KroniKare Pte Ltd. is a technology company that specializes in AI-driven diagnostic solutions for chronic wound assessment and management, facilitating rapid and precise evaluations to improve patient care. Founded in 2017, KroniKare Pte Ltd. is based in Singapore and focuses on developing innovative solutions for chronic wound management.

The company was co-founded by Ali Aladdin and Hossein Nejati, with Ali Aladdin serving as the CEO. KroniKare has successfully completed a Series A funding round, raising USD 1. 3 mn from investors including Angel Central Syndicate, Anthill Ventures, and Essex Bio-Technology Limited, bringing its total funds raised to USD 1. 3 mn and a current valuation of USD 5.

213 mn. The company has engaged in three deals to date, indicating its proactive approach in the healthcare technology sector. KroniKare specializes in AI-driven diagnostic technology focused on chronic wound assessment and management. Its core product, the KroniKare Wound Scanner, utilizes patented Portable Multi-Spectral Scanner technology to provide rapid, non-invasive wound assessments in under 30 seconds.

This device integrates over 15 years of systematic data capture and employs advanced AI algorithms to perform automatic 3D measurements, allowing healthcare practitioners to make informed treatment decisions quickly. The scanner is particularly beneficial for hospitals, rehabilitation centers, and home care settings, enhancing continuity of care for patients across various stages of treatment. Notable clients include Kwong Wai Shiu Hospital, which has reported improved patient outcomes and efficiency. KroniKare's products are marketed primarily in Southeast Asia and are expanding into global markets aimed at healthcare facilities requiring innovative solutions for chronic wound management.

In 2019, KroniKare reported a revenue of USD 11,812. 3 while experiencing an EBITDA loss of USD 777,108. 8. The company generates revenue through direct sales of its flagship products to healthcare institutions and partnerships that facilitate technology integration into existing medical frameworks.

The transaction structure typically involves B2B agreements with hospitals and rehabilitation centers, where the KroniKare Wound Scanner is sold as a one-time purchase or through a subscription model for software updates and support services. The pricing structure is determined based on the specific needs of healthcare providers, which may include bulk purchases or long-term service contracts. The company also collaborates with technology partners like Intel to enhance product offerings and market penetration, contributing to ongoing revenue streams through joint ventures and collaborative projects. KroniKare Pte Ltd.

plans to leverage its recent Series A funding of USD 1. 3 mn to accelerate the development and market launch of new products aimed at enhancing chronic wound management. The company is strategically targeting expansion into new geographic regions including North America and Europe by the end of 2024. This initiative will focus on establishing partnerships with leading healthcare providers to integrate its innovative solutions into their facilities.

Additionally, the recent funding will support marketing efforts to increase brand awareness in these new markets.